Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?

被引：0
作者：
Lemieux, Alexandre [1 ]
Saber, Melissa [1 ]
Cote, Benoit [1 ]
机构：
[1] Ctr Hosp Univ Montreal, Serv Dermatol, Dept Med, 1000 Rue St Denis, Montreal, PQ, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2022年 / 26卷 / 01期
关键词：
pemphigus; rituximab; mycophenolate mofetil; treatment; THERAPY;
D O I：
10.1177/12034754211035098
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [31] Combination of Ibrutinib with Rituximab Versus Placebo with Rituximab for First-Line Treatment of Follicular Lymphoma: PERSPECTIVE, a Randomized Phase 3 Study
    Flinn, Ian
    Gordon, Leo
    Rule, Simon
    Chen, Robert
    Kwei, Long
    Chu, Alvina D.
    Fowler, Nathan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S277 - S278
  • [32] Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia
    Mueller, Dirk
    Fischer, Kirsten
    Kaiser, Peter
    Eichhorst, Barbara
    Walshe, Ronald
    Reiser, Marcel
    Kellermann, Lenka
    Borsi, Lisa
    Civello, Daniele
    Mensch, Alexander
    Bahlo, Jasmin
    Hallek, Michael
    Stock, Stephanie
    Fingerle-Rowson, Guenter
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1130 - 1139
  • [33] First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
    Joly, Pascal
    Maho-Vaillant, Maud
    Prost-Squarcioni, Catherine
    Hebert, Vivien
    Houivet, Estelle
    Calbo, Sebastien
    Caillot, Frederique
    Golinski, Marie Laure
    Labeille, Bruno
    Picard-Dahan, Catherine
    Paul, Carle
    Richard, Marie-Aleth
    Bouaziz, Jean David
    Duvert-Lehembre, Sophie
    Bernard, Philippe
    Caux, Frederic
    Alexandre, Marina
    Ingen-Housz-Oro, Saskia
    Vabres, Pierre
    Delaporte, Emmanuel
    Quereux, Gaelle
    Dupuy, Alain
    Debarbieux, Sebastien
    Avenel-Audran, Martine
    D'Incan, Michel
    Bedane, Christophe
    Beneton, Nathalie
    Jullien, Denis
    Dupin, Nicolas
    Misery, Laurent
    Machet, Laurent
    Beylot-Barry, Marie
    Dereure, Olivier
    Sassolas, Bruno
    Vermeulin, Thomas
    Benichou, Jacques
    Musette, Philippe
    LANCET, 2017, 389 (10083) : 2031 - 2040
  • [34] Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients
    Giulio Tessarin
    Manuela Baronio
    Luisa Gazzurelli
    Stefano Rossi
    Marco Chiarini
    Daniele Moratto
    Silvia Clara Giliani
    Maria Pia Bondioni
    Raffaele Badolato
    Vassilios Lougaris
    Journal of Clinical Immunology, 2023, 43 : 2091 - 2103
  • [35] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [36] Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study
    Malard, Florent
    Labopin, Myriam
    Yakoub-Agha, Ibrahim
    Chantepie, Sylvain
    Guillaume, Thierry
    Blaise, Didier
    Tabrizi, Reza
    Magro, Leonardo
    Vanhove, Bernard
    Blancho, Gilles
    Moreau, Philippe
    Gaugler, Beatrice
    Chevallier, Patrice
    Mohty, Mohamad
    BLOOD, 2017, 130 (20) : 2186 - 2195
  • [37] An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
    Ray, Joshua A.
    Carr, Emma
    Lewis, Gavin
    Marcus, Robert
    VALUE IN HEALTH, 2010, 13 (04) : 346 - 357
  • [38] Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients
    Tessarin, Giulio
    Baronio, Manuela
    Gazzurelli, Luisa
    Rossi, Stefano
    Chiarini, Marco
    Moratto, Daniele
    Giliani, Silvia Clara
    Bondioni, Maria Pia
    Badolato, Raffaele
    Lougaris, Vassilios
    JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (08) : 2091 - 2103
  • [39] Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis
    McGonagle, D.
    Tan, A. L.
    Madden, J.
    Taylor, L.
    Emery, P.
    RHEUMATOLOGY, 2008, 47 (06) : 865 - 867
  • [40] First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas
    Roberto Castelli
    Luigi Bergamaschini
    Giorgio Lambertenghi Deliliers
    Medical Oncology, 2018, 35
12345